Apogee Therapeutics, Inc. Common Stock
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treat… Read more
Market Cap & Net Worth: Apogee Therapeutics, Inc. Common Stock (APGE)
Apogee Therapeutics, Inc. Common Stock (NASDAQ:APGE) has a market capitalization of $3.87 Billion ($3.87 Billion) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3503 globally and #2294 in its home market, demonstrating a -6.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Apogee Therapeutics, Inc. Common Stock's stock price $69.85 by its total outstanding shares 55361011 (55.36 Million).
Apogee Therapeutics, Inc. Common Stock Market Cap History: 2023 to 2026
Apogee Therapeutics, Inc. Common Stock's market capitalization history from 2023 to 2026. Data shows growth from $1.55 Billion to $3.87 Billion (69.45% CAGR).
Index Memberships
Apogee Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.16% | #81 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.01% | #428 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.24% | #51 of 263 |
Weight: Apogee Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Apogee Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Apogee Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of APGE by Market Capitalization
Companies near Apogee Therapeutics, Inc. Common Stock in the global market cap rankings as of March 18, 2026.
Key companies related to Apogee Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Apogee Therapeutics, Inc. Common Stock Historical Marketcap From 2023 to 2026
Between 2023 and today, Apogee Therapeutics, Inc. Common Stock's market cap moved from $1.55 Billion to $ 3.87 Billion, with a yearly change of 69.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.87 Billion | -7.46% |
| 2025 | $4.18 Billion | +66.62% |
| 2024 | $2.51 Billion | +62.13% |
| 2023 | $1.55 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Apogee Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.87 Billion USD |
| MoneyControl | $3.87 Billion USD |
| MarketWatch | $3.87 Billion USD |
| marketcap.company | $3.87 Billion USD |
| Reuters | $3.87 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.